NYSE · BRK-B
Berkshire Hathaway Inc.
$541.96+$1.62 (+0.3%)
Berkshire Hathaway Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.45% below the high.
Loading market information…
OTC · ONPH · USD
Stock price, earnings
Quote as of Oct 29, 2026, 07:43 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Oncology Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.11% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Oncology Pharma Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Oncology Pharma Inc. is a pharmaceutical firm specializing in oncology, dedicated to the development, manufacturing, and commercialization of therapeutic agents. The company has a collaborative and licensing agreement with Kalos Therapeutics Inc. to explore treatment possibilities for the COVID-19 virus. Originally incorporated in 1993, the company was known as SourcingLink.net Inc. until it rebranded as Oncology Pharma Inc. in June 2019. Its operations are based in San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$541.96+$1.62 (+0.3%)
Berkshire Hathaway Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.45% below the high.
$343.58+$4.28 (+1.26%)
JPMorgan Chase & Co.’s quoted price sits in the upper half of its reported 52-week range, 6.25% below the high.
$410.54+$9.94 (+2.48%)
Visa Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.98% below the high.
$635.70+$25.39 (+4.16%)
Mastercard Incorporated’s quoted price sits in the upper half of its reported 52-week range, 0.91% below the high.
$51.14+$0.29 (+0.57%)
Bank of America Corporation’s quoted price sits in the lower half of its reported 52-week range, 21.6% below the high.
$190.00-$0.13 (-0.07%)
Morgan Stanley’s quoted price sits in the lower half of its reported 52-week range, 18.19% below the high.
$0.18$0.00 (0.0%)
Ampio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.55% below the high.
$0.00$0.00 (0.0%)
Wuhan General Group (China), Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
